- Home
- BRBI vs LXEO Comparison
BRBI vs LXEO Comparison
Compare BRBI & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | BRBI | LXEO |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | Brazil | United States |
| Employees | 188 | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 383.0M | 369.8M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | BRBI | LXEO |
|---|---|---|
| Price | $12.77 | $5.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $18.44 |
| AVG Volume (30 Days) | 1.1K | ★ 667.0K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.03% | N/A |
| EPS Growth | N/A | ★ 39.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.24 | N/A |
| P/E Ratio | $11.72 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.54 | $2.72 |
| 52 Week High | $67.01 | $10.99 |
Technical Indicators
Market Signals| Indicator | BRBI | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 31.70 | 43.41 |
| Support Level | $12.76 | $4.95 |
| Resistance Level | $15.06 | $6.26 |
| Average True Range (ATR) | 0.20 | 0.38 |
| MACD | -0.15 | 0.00 |
| Stochastic Oscillator | 0.00 | 36.34 |
Price Performance
Historical ComparisonAbout BRBI BRBI BR Partners S.A. ADSs
BRBI BR Partners SA, formerly BR Advisory Partners Participacoes SA, is engaged in investing in other companies, domestic or foreign, as a partner, quota holder, or shareholder, and management of its assets. It has a single reportable segment being investment banking services, which are administered and managed according to the products offered.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.